Safety of Megadose Meropenem in the Empirical Treatment of Nosocomial Sepsis: A Pilot Randomized Clinical Trial

Safety of Megadose Meropenem in the Empirical Treatment of Nosocomial Sepsis: A Pilot Randomized Clinical Trial Publisher Pubmed

Salehi M¹ ; Rezazademoayed F¹ ; Khalili H² ; Hemati H² ; Aghdami N^{1, 3} ; Dashtkoohi M⁴ ; Dashtkoohi M⁴ ; Beigmohammadi MT⁵ ; Ramezani M⁵ ; Hajiabdolbaghi M¹ ; Fattahghazi S⁵

Show Affiliations

1. Research Center for Antibiotic Stewardship and Antimicrobial Resistance, Imam Khomeini Hospital Complex, Department of Infectious Diseases, Tehran University of Medical Sciences, Tehran, Iran
2. Research Center for Antibiotic Stewardship and Antimicrobial Resistance, Imam Khomeini Hospital Complex, Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
3. Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology & Technology, Academic Center for Education, Culture & Research, Tehran, Iran
4. Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran
5. Critical Care Department, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

Source: Future Microbiology Published:2023

Abstract

Objective: To evaluate the safety of megadose meropenem as empirical treatment of nosocomial sepsis. Materials & methods: Critically ill patients diagnosed with sepsis received either high-dose (2 g every 8 h) or megadose (4 g every 8 h) meropenem as an intravenous infusion over 3 h. Results: A total of 23 patients with nosocomial sepsis were eligible and included in the megadose (n = 11) or high-dose (n = 12) group. No treatment-related adverse events were observed during a 14-day follow-up. Clinical response was also comparable between the groups. Conclusion: Megadose meropenem may be considered for empirical treatment of nosocomial sepsis without serious concern regarding its safety. Plain language summary As resistance to antibiotics is increasing among microbes, rational use of these drugs is important both in the community and in hospitals. Many infections with resistant microorganisms may be fatal. For a long time, carbapenems have been the last resort for treatment of resistant microorganisms. Unfortunately, resistance to these drugs is increasing. It appears that use of higher doses of antibiotics may help in some cases. However, the potential harm caused by higher doses is a problem. In this primary study, higher doses of meropenem, a common carbapenem, were found to be safe. © 2023 Future Medicine Ltd.

Style	Citing Format
MLA	Salehi M, et al.. "Safety of Megadose Meropenem in the Empirical Treatment of Nosocomial Sepsis: A Pilot Randomized Clinical Trial." Future Microbiology, vol. 18, no. 6, 2023, pp. 335-342.
APA	Salehi M, Rezazademoayed F, Khalili H, Hemati H, Aghdami N, Dashtkoohi M, Dashtkoohi M, Beigmohammadi MT, Ramezani M, Hajiabdolbaghi M, Fattahghazi S (2023). Safety of Megadose Meropenem in the Empirical Treatment of Nosocomial Sepsis: A Pilot Randomized Clinical Trial. Future Microbiology, 18(6), 335-342.
Chicago	Salehi M, Rezazademoayed F, Khalili H, Hemati H, Aghdami N, Dashtkoohi M, Dashtkoohi M, et al.. "Safety of Megadose Meropenem in the Empirical Treatment of Nosocomial Sepsis: A Pilot Randomized Clinical Trial." Future Microbiology 18, no. 6 (2023): 335-342.
Harvard	Salehi M et al. (2023) 'Safety of Megadose Meropenem in the Empirical Treatment of Nosocomial Sepsis: A Pilot Randomized Clinical Trial', Future Microbiology, 18(6), pp. 335-342.
Vancouver	Salehi M, Rezazademoayed F, Khalili H, Hemati H, Aghdami N, Dashtkoohi M, et al.. Safety of Megadose Meropenem in the Empirical Treatment of Nosocomial Sepsis: A Pilot Randomized Clinical Trial. Future Microbiology. 2023;18(6):335-342.
BibTex	@article{ author = {Salehi M and Rezazademoayed F and Khalili H and Hemati H and Aghdami N and Dashtkoohi M and Dashtkoohi M and Beigmohammadi MT and Ramezani M and Hajiabdolbaghi M and Fattahghazi S}, title = {Safety of Megadose Meropenem in the Empirical Treatment of Nosocomial Sepsis: A Pilot Randomized Clinical Trial}, journal = {Future Microbiology}, volume = {18}, number = {6}, pages = {335-342}, year = {2023} }
RIS	TY - JOUR AU - Salehi M AU - Rezazademoayed F AU - Khalili H AU - Hemati H AU - Aghdami N AU - Dashtkoohi M AU - Dashtkoohi M AU - Beigmohammadi MT AU - Ramezani M AU - Hajiabdolbaghi M AU - Fattahghazi S TI - Safety of Megadose Meropenem in the Empirical Treatment of Nosocomial Sepsis: A Pilot Randomized Clinical Trial JO - Future Microbiology VL - 18 IS - 6 SP - 335 EP - 342 PY - 2023 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract